Comprehensive GMP Laboratory Testing Services
From Starting Materials through Finished Product Testing, Eurofins BioPharma Product Testing’s 28 facilities in 16 countries deliver the most comprehensive scope of harmonized GMP testing services and seamless regulatory acceptance.
From Starting Materials through Finished Product Testing, Eurofins BioPharma Product Testing’s 28 facilities in 16 countries deliver the world’s most comprehensive scope of harmonized GMP testing services and seamless regulatory acceptance.
As we have grown to become the world’s largest network of GMP product testing labs with a global capacity of more than 115,000 square meters, we continue to uphold our founding promise of personal service and impeccable quality. With facilities located in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, India, Netherlands, New Zealand, Spain, Sweden, Switzerland, UK and the US, our network of laboratories and vast experience allow us to support projects of any size from conception to market.
We offer the flexibility to manage your testing programs more efficiently through your choice of three unique service models, including our award-winning Professional Scientific Services® (PSS), Full Time Equivalent (FTE) or traditional fee-for-service. You can choose the best, most cost-effective service solution for your project goals.
When the world awaits your product, choose the lab that provides complete capabilities and rigorous quality systems you can trust.
Contact Details:
Company name: Eurofins BioPharma Product Testing
Website: www.Eurofins.com/BioPharma
E-mail: pharma@eurofins.com
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
